Endometrial Cancer
If it’s your first time on this website, please read the disclaimer section.
May 04 – May 11, 2026
Tumor-Infiltrating Clonal Hematopoiesis and Pan-Cancer Prognosis in Patients With Solid Tumors.
JAMA ONCOL · Q1 JOURNAL - RANK #14/326TOP-TIER
This retrospective cohort study analyzed whole-genome sequencing data from 10,571 patients with solid tumors to evaluate the prevalence and prognostic impact of tumor-infiltrating clonal hematopoiesis (TI-CH). TI-CH was identified in 18.38% of patients, occurring most frequently in endometrial cancer (32%) and correlating with older age and prior cytotoxic chemotherapy. Results demonstrated that TI-CH is significantly associated with worse pan-cancer overall survival (HR 1.13), with particularly high risk observed in breast cancer patients (HR 1.95) and those with GATA2 variants (HR 3.00). These findings suggest that TI-CH serves as a valuable prognostic biomarker across various solid tumors, potentially refining risk stratification and personalized treatment strategies in oncology.
10.1001/jamaoncol.2026.1036
Apr 13 – Apr 20, 2026
Endometrial Cancer: A Review.
JAMA-J AM MED ASSOC · Q1 JOURNAL - RANK #4/332TOP-TIER
This comprehensive review examines the epidemiology, pathophysiology, and management of endometrial cancer, which represents 95% of uterine cancers and is the fourth most common cancer in US women. Key findings highlight a rising mortality rate (5.6 per 100,000) and significant racial disparities, with 5-year survival rates ranging from over 86% for stage I to 18% for stage IV disease. The study details a clinical pathway involving surgical staging followed by risk-stratified adjuvant therapies, including radiation, carboplatin-paclitaxel chemotherapy, and anti-PD-1 immunotherapy for advanced cases. These findings emphasize the necessity of early diagnostic evaluation for vaginal bleeding and the integration of molecular subtyping to optimize treatment outcomes in a growing patient population.
10.1001/jama.2026.2248
Mar 02 – Mar 09, 2026
Assessing the global demand and supply of brachytherapy resources: a population-based observational study.
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
This population-based observational study quantified the global demand and supply of brachytherapy resources for six specific cancers, utilizing cancer incidence data from GLOBOCAN 2022 and brachytherapy centre data. It found that 708,948 of 18.5 million new cancer cases in 2022 required brachytherapy, with cervical cancer accounting for 59.3% of indications. Brachytherapy demand was met in 81.5% of HICs but in no LICs, with patients in LICs traveling an average of 551 km compared to 68 km in HICs. These findings highlight profound global inequities in access to this critical cancer treatment, underscoring an urgent need for investment in new centers to improve cancer care worldwide.
10.1016/S1470-2045(25)00718-1